U.S. Markets open in 4 hrs 27 mins

Wired News – ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World

Stock Monitor: Hemispherx Biopharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARQL as the Company's latest news hit the wire. On April 17, 2018, the Company announced on that it has signed an exclusive license deal with Switzerland-based Basilea Pharmaceutica International Ltd ("Basilea"), to develop and commercialize ArQule's oncology drug candidate, derazantinib, in the US, EU, Japan, and rest of the world excluding the People's Republic of China, Hong Kong, Macau, and Taiwan. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Hemispherx Biopharma, Inc. (NYSE AMER: HEB), which also belongs to the Healthcare sector as the Company ArQule. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ArQule most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Terms of the Deal

  • Basilea will make an upfront payment of $10 million to ArQule and additional $326 million in regulatory and commercial milestones payments.
  • ArQule will also receive staggered single-digit to double-digit royalties on net sales upon commercialization.
  • Basilea will be responsible for all costs and expenses of development, manufacture, and commercialization in its territory. Under certain circumstances, ArQule may have the opportunity to promote derazantinib in the US directly.
  • ArQule is currently conducting a registrational trial for derazantinib in the United States, Canada, and Europe as a potential treatment for intrahepatic cholangiocarcinoma (iCCA), a form of biliary tract cancer. As part of the license agreement, Basilea intends to continue this trial and the further development of derazantinib in iCCA and other tumor types with FGFR dysregulation.

Derazantinib is an Ideal Match for Basilea's Existing Clinical Oncology Portfolio

Commenting on the agreement, Ronald Scott, Chief Executive Officer of Basilea, stated that Derazantinib is an ideal match for Basilea's existing clinical oncology portfolio. This transaction underscores Basilea's continued commitment to expand its R&D portfolio with novel compounds focused on overcoming the clinical problem of resistance in oncology and infectious diseases.

Ronald added that the Company's clinical oncology portfolio now includes three drug candidates in different stages of development.

Basilea will Bring a Wealth of Skills to the Expansion of the Derazantinib Development Plan

Paolo Pucci, Chief Executive Officer of ArQule, mentioned that partnering with Basilea, a company with global drug development experience and expertise, will propel the advancement of derazantinib in ways ArQule could not have achieved independently.

Paolo added that Basilea will bring a wealth of skills to the expansion of the derazantinib development plan at a time when it will benefit most from these resources, allowing it to reach its full potential in iCCA and beyond.

ArQule Out-Licenses Derazantinib to Roivant in China, Hong Kong, Macau, and Taiwan

On February 07, 2018, Roivant Sciences and ArQule announced the initiation of a collaboration to pursue the development of derazantinib in Greater China. As part of the collaboration, ArQule granted a Roivant subsidiary, Sinovant Sciences Ltd, an exclusive license to develop and commercialize derazantinib in the People's Republic of China, Hong Kong, Macau, and Taiwan.

About Derazantinib

Derazantinib (ARQ 087) is an investigational, oral, multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases with demonstrated activity in FGFR2 genetic alterations, including fusions. The drug has demonstrated favorable clinical data in a biomarker-driven Phase-1/2 trial in iCCA targeting patients with FGFR2 fusions. Both the FDA and EMA have granted ArQule orphan drug designation for this disease.

About ArQule, Inc.

Founded in 1993 and headquartered in Burlington, Massachusetts, ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

About Basilea Pharmaceutica International Ltd

Based in Basel, Switzerland, Basilea is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections, and cancer.

Stock Performance Snapshot

April 18, 2018 - At Wednesday's closing bell, ArQule's stock marginally dropped 0.95%, ending the trading session at $3.13.

Volume traded for the day: 4.79 million shares, which was above the 3-month average volume of 734.21 thousand shares.

Stock performance in the last month – up 34.91%; previous three-month period – up 81.98%; past twelve-month period – up 226.04%; and year-to-date - up 89.70%

After yesterday's close, ArQule's market cap was at $281.48 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors